Russell Investments Group Ltd. Grows Position in 10x Genomics $TXG

Key Points

• Russell Investments Group Ltd. increased its stake in 10x Genomics by 385.6%, acquiring an additional 64,851 shares, bringing its total ownership to 81,669 shares valued at approximately $713,000.
• 10x Genomics reported $0.28 earnings per share for the most recent quarter, surpassing analyst expectations of ($0.35) and achieving a revenue of $172.91 million.
• Wall Street analysts have mixed ratings on 10x Genomics, with six equities analysts recommending a Buy, six a Hold, and one a Sell, reflecting uncertainty in stock performance.

Russell Investments Group Ltd. increased its holdings in shares of 10x Genomics (NASDAQ:TXG - Free Report) by 385.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 81,669 shares of the company's stock after acquiring an additional 64,851 shares during the quarter. Russell Investments Group Ltd. owned about 0.07% of 10x Genomics worth $713,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. Nuveen LLC bought a new stake in shares of 10x Genomics during the 1st quarter worth about $1,755,000. Invesco Ltd. boosted its holdings in shares of 10x Genomics by 62.1% during the first quarter. Invesco Ltd. now owns 191,332 shares of the company's stock worth $1,670,000 after acquiring an additional 73,265 shares during the period. Benjamin Edwards Inc. grew its position in shares of 10x Genomics by 10.3% in the first quarter. Benjamin Edwards Inc. now owns 77,155 shares of the company's stock valued at $674,000 after purchasing an additional 7,229 shares during the last quarter. Chicago Partners Investment Group LLC bought a new position in shares of 10x Genomics during the first quarter worth approximately $119,000. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of 10x Genomics by 20.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 648,410 shares of the company's stock worth $5,661,000 after purchasing an additional 108,744 shares during the period. 84.68% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Weiss Ratings reiterated a "sell (e+)" rating on shares of 10x Genomics in a research report on Saturday. Wall Street Zen upgraded shares of 10x Genomics from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. JPMorgan Chase & Co. dropped their price objective on 10x Genomics from $12.00 to $9.00 and set a "neutral" rating for the company in a report on Friday, May 9th. Canaccord Genuity Group set a $16.00 price target on 10x Genomics in a research note on Monday, August 11th. Finally, Barclays reiterated an "overweight" rating and set a $15.00 price objective (up from $13.00) on shares of 10x Genomics in a research note on Friday, August 8th. Six investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $13.54.

10x Genomics Price Performance

Shares of 10x Genomics stock traded down $0.27 during trading on Monday, hitting $14.01. The company's stock had a trading volume of 1,566,109 shares, compared to its average volume of 3,022,419. The stock has a market cap of $1.74 billion, a price-to-earnings ratio of -20.01 and a beta of 2.00. 10x Genomics has a 52 week low of $6.78 and a 52 week high of $24.76. The stock has a 50-day moving average price of $12.98 and a two-hundred day moving average price of $10.70.

10x Genomics (NASDAQ:TXG - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.63. The company had revenue of $172.91 million for the quarter, compared to the consensus estimate of $139.36 million. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The firm's revenue was up 12.9% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. On average, equities analysts predict that 10x Genomics will post -1.43 EPS for the current fiscal year.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, CFO Adam Taich sold 22,315 shares of 10x Genomics stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $307,723.85. Following the completion of the transaction, the chief financial officer owned 309,273 shares in the company, valued at approximately $4,264,874.67. The trade was a 6.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Benjamin J. Hindson sold 7,486 shares of 10x Genomics stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $103,231.94. Following the transaction, the insider directly owned 440,888 shares in the company, valued at approximately $6,079,845.52. The trade was a 1.67% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 39,149 shares of company stock valued at $539,865. Corporate insiders own 10.03% of the company's stock.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.